Multiple Histology Phase II Trials.

Area of Science:

• Oncology
• Biostatistics
• Clinical Trial Design

Background:

• Testing new cancer treatments across diverse subtypes presents statistical and logistical hurdles.
• Treatment efficacy can vary significantly between different histological or biological subtypes.

Purpose of the Study:

• To propose a flexible phase II clinical trial strategy for cancers with multiple subtypes.
• To address challenges in evaluating new treatments with potentially heterogeneous responses.
• To incorporate both stratum-specific and combined analyses for comprehensive evaluation.

Main Methods:

• Developed a flexible phase II strategy integrating stratum-specific and combined analyses.
• Utilized simulation studies and a soft tissue sarcoma phase II trial for assessment.
• Incorporated sequential futility analyses for early stopping criteria.

Main Results:

• The combined analysis approach reduces expected sample sizes when treatments are broadly inactive.
• It enhances statistical power for detecting modest activity across multiple subtypes compared to separate trials.
• Stratum-specific tests enable the identification of patient subgroups with the most significant treatment response.

Conclusions:

• The proposed strategy offers promising statistical properties for phase II trials in heterogeneous cancers.
• Statistical information borrowing across subgroups is beneficial in phase II studies.
• Recommends inclusive patient enrollment in phase II trials with subgroup-specific design considerations.